[1] JIAN Z, ZENG L, XU T, et al.Antibiotic resistance genes in bacteria:Occurrence, spread, and control[J].Journal of Basic Microbiology, 2021, 61(12):1049-1070. [2] SCHMID A, WOLFENSBERGER A, NEMETH J, et al.Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections:Systematic review and Meta-analysis[J].Scientific Reports, 2019, 9(1):15290. [3] VARMA G Y N, KUMMARI G, PAIK P, et al.Celecoxib potentiates antibiotic uptake by altering membrane potential and permeability in Staphylococcus aureus[J].Journal of Antimicrobial Chemotherapy, 2019, 74(12):3462-3472. [4] SU J C, HUANG Y T, CHEN C S, et al.Design and synthesis of malonamide derivatives as antibiotics against methicillin-resistant Staphylococcus aureus[J].Molecules, 2018, 23(1):27. [5] KIM W, ZHU W, HENDRICKS G L, et al.A new class of synthetic retinoid antibiotics effective against bacterial persisters[J].Nature, 2018, 556(7699):103-107. [6] CHIN W, ZHONG G, PU Q, et al.A macromolecular approach to eradicate multidrug resistant bacterial infections while mitigating drug resistance onset[J].Nature Communications, 2018, 9(1):917. [7] ROCH M, VARELA M C, TAGLIALEGNA A, et al.Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients[J].The Journal of Antimicrobial Chemotherapy, 2020, 75(1):126-134. [8] COCHRANE S A, LI X, HE S, et al.Synthesis of tridecaptin-antibiotic conjugates with in vivo activity against Gram-negative bacteria[J].Journal of Medicinal Chemistry, 2015, 58(24):9779-9785. [9] SCHOOLEY R T, STRATHDEE S.Treat phage like living antibiotics[J].Nature Microbiology, 2020, 5(3):391-392. [10] HHUANG Y, WANG W, ZHANG Z, et al.Phage products for fighting antimicrobial resistance[J].Microorganisms, 2022, 10(7):1324. [11] TKHILAISHVILIKH T, WANG L, TAVANTI A, et al.Antibacterial efficacy of two commercially available bacteriophage formulations, staphylococcal bacteriophage and PYO bacteriophage, against methicillin-resistant Staphylococcus aureus:Prevention and eradication of biofilm formation and control of a systemic infection of Galleria mellonella larvae[J].Frontiers in Microbiology, 2020, 11:110. [12] SELLE K, FLETCHER J R, TUSON H, et al. In vivo targeting of Clostridioides difficile using phage-delivered CRISPR-Cas3 antimicrobials[J].mBio, 2020, 11(2):e00019-20. [13] NGUYEN N T, GRELLING N, WETTELAND C L, et al.Antimicrobial activities and mechanisms of magnesium oxide nanoparticles (nMgO) against pathogenic bacteria, yeasts, and biofilms[J].Scientific Reports, 2018, 8(1):16260. [14] HURDLE J G, O'NEILL A J, CHOPRA I, et al.Targeting bacterial membrane function:An underexploited mechanism for treating persistent infections[J].Nature Reviews Microbiology, 2011, 9(1):62-75. [15] SHE P F, LIU Y Q, XU L L, et al.L007-0069 kills Staphylococcus aureus in high resistant phenotypes[J].Cellular and Molecular Life Sciences, 2022, 79(11):552. [16] TALBOT G H, JEZEK A, MURRAY B E, et al.The Infectious Diseases Society of America's 10×'20 initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020):Is 20×'20 a possibility?[J].Clinical Infectious Diseases, 2019, 69(1):1-11. [17] BALD D, VILLELLAS C, LU P, et al.Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in antimycobacterial drug discovery[J].mBio, 2017, 8(2):e00272-17. [18] BAHUGUNA A, RAWAT S, RAWAT D S.QcrB in Mycobacterium tuberculosis:The new drug target of antitubercular agents[J].Medicinal Research Reviews, 2021, 41(4):2565-2581. [19] KRISHNAMURTHY M, LEMMON M M, FALCINELLI E M, et al.Enhancing the antibacterial activity of polymyxins using a nonantibiotic drug[J].Infection and Drug Resistance, 2019, 12:1393-1405. [20] TZENG S R, HUANG Y W, ZHANG Y Q, et al.A celecoxib derivative eradicates antibiotic-resistant Staphylococcus aureus and biofilms by targeting YidC2 translocase[J].International Journal of Molecular Sciences, 2020, 21(23):9312. [21] SHAHREZA M L, GHADIRI N, MOUSAVI S R, et al.A review of network-based approaches to drug repositioning[J].Briefings in Bioinformatics, 2018, 19(5):878-892. [22] RAO N, POOJARI T, POOJARY C, et al.Drug repurposing:A shortcut to new biological entities[J].Pharmaceutical Chemistry Journal, 2022, 56(9):1203-1214. [23] JOURDAN J P, BUREAU R, ROCHAIS C, et al.Drug repositioning:A brief overview[J].Journal of Pharmacy and Pharmacology, 2020, 72(9):1145-1151. [24] CARLSON-BANNING K M, CHOU A, LIU Z, et al.Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae[J].PLoS One, 2013, 8(7):e69646. [25] STOKES J M, MACNAIR C R, ILYAS B, et al.Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance[J].Nature Microbiology, 2017, 2:17028. [26] CEBRERO-CANGUEIRO T, ÁLVAREZl-MARÍN R, LABRADOR-HERRERA G, et al.In vitro activity of pentamidine alone and in combination with aminoglycosides, tigecycline, rifampicin, and doripenem against clinical strains of carbapenemase-producing and/or colistin-resistant Enterobacteriaceae[J].Frontiers in Cellular and Infection Microbiology, 2018, 8:363. [27] TYERS M, WRIGHT G D.Drug combinations:A strategy to extend the life of antibiotics in the 21st century[J].Nature Reviews Microbiology, 2019, 17(3):141-155. [28] YU Y, WALSH T R, YANG R S, et al.Novel partners with colistin to increase its in vivo therapeutic effectiveness and prevent the occurrence of colistin resistance in NDM- and MCR-co-producing Escherichia coli in a murine infection model[J].Journal of Antimicrobial Chemotherapy, 2019, 74(1):87-95. [29] GONZÁLEZ-BELLO C.Antibiotic adjuvants-A strategy to unlock bacterial resistance to antibiotics[J].Bioorganic & Medicinal Chemistry Letters, 2017, 27(18):4221-4228. [30] CHAWLA M, VERMA J, GUPTA R, et al.Antibiotic potentiators against multidrug-resistant bacteria:Discovery, development, and clinical relevance[J].Frontiers in Microbiology, 2022, 13:887251. [31] SUN H, ZHANG Q, WANG R, et al.Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin[J].Nature Communications, 2020, 11(1):5263. [32] LIU Y, JIA Y, YANG K, et al.Metformin restores tetracyclines susceptibility against multidrug resistant bacteria[J].Advanced Science, 2020, 7(12):1902227. [33] FERNANDES P, MARTENS E.Antibiotics in late clinical development[J].Biochemical Pharmacology, 2017, 133:152-163. [34] ZHANEL G G, LAWRENCE C K, ADAM H, et al.Imipenem-relebactam and meropenem-vaborbactam:Two novel carbapenem-β-lactamase inhibitor combinations[J].Drugs, 2018, 78(1):65-98. [35] HINCHLIFFE P, GONZALEZ M M, MOJICA M F, et al.Cross-class metallo-beta-lactamase inhibition by bisthiazolidines reveals multiple binding modes[J].Proceedings of the National Academy of Sciences of the Nnited States of America, 2016, 113(26):E3745-E3754. [36] WANG R, LAI T P, GAO P, et al.Bismuth antimicrobial drugs serve as broad-spectrum metallo-beta-lactamase inhibitors[J].Nature Communications, 2018, 9(1):439. [37] WANG Y, MOWLA R, GUO L, et al.Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance[J].Bioorganic & Medicinal Chemistry Letters, 2017, 27(4):733-739. [38] SINGH S, KALIA N P, JOSHI P, et al.Boeravinone B, a novel dual inhibitor of NorA bacterial efflux pump of Staphylococcus aureus and human P-glycoprotein, reduces the biofilm formation and intracellular invasion of bacteria[J].Frontiers in Microbiology, 2017, 8:1868. [39] SUN W, HE S, MARTÍNEZ-ROMERO C, et al.Synergistic drug combination effectively blocks Ebola virus infection[J].Antiviral Research, 2017, 137:165-172. [40] MANOLIS E, BROGREN J, COLE S, et al.Commentary on the MID3 good practices paper[J].CPT Pharmacometrics and Systems Pharmacology, 2017, 6(7):416-417. [41] KIMKO H, PINHEIRO J.Model-based clinical drug development in the past, present and future:A commentary[J].British Journal of Clinical Pharmacology, 2015, 79(1):108-116. [42] PLOEGER B A, GRAAF P H, DANHOF M.Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling[J].Drug Metabolism and Pharmacokinetics, 2009, 24(1):3-15. [43] KRISTOFFERSSON A N, BISSANTZ C, OKUJAVA R, et al.A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against beta-lactamase-producing Gram-negative bacteria[J].Journal of Antimicrobial Chemotherapy, 2020, 75(2):400-408. [44] BIAN X, LIU X, CHEN Y, et al.Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in vitro pharmacokinetic/pharmacodynamic model[J].Antimicrobial Agents and Chemotherapy, 2019, 63(4):e01989-18. [45] SY S, ZHUANG L, XIA H, et al.Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms[J].CPT:Pharmacometrics & Systems Pharmacology, 2017, 6(3):197-207. [46] RAMOS P I P, FERNÁNDEZ D P, LANZAROTTI E, et al.An integrative, multi-omics approach towards the prioritization of Klebsiella pneumoniae drug targets[J].Scientific Reports, 2018, 8(1):10755. [47] HENDRIKSEN R S, BORTOLAIA V, TATE H, et al.Using genomics to track global antimicrobial resistance[J].Frontiers in Public Health, 2019, 7:242. [48] PORNSUKAROM S, VLIET A H M, THAKUR S.Whole genome sequencing analysis of multiple Salmonella serovars provides insights into phylogenetic relatedness, antimicrobial resistance, and virulence markers across humans, food animals and agriculture environmental sources[J].BMC Genomics, 2018, 19(1):801. [49] RICHARDS V P, VELSKO I M, ALAM T, et al.Population gene introgression and high genome plasticity for the zoonotic pathogen Streptococcus agalactiae[J].Molecular Biology and Evolution, 2019, 36(11):2572-2590. [50] BRUGER E L, MARX C J.A decade of genome sequencing has revolutionized studies of experimental evolution[J].Current Opinion in Microbiology, 2018, 45:149-155. [51] DEATHERAGE D E, BARRICK J E.Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq[J].Methods in Molecular Biology, 2014, 1151:165-188. [52] KHOURY J Y, MAURE A, GINGRAS H, et al.Chemogenomic screen for imipenem resistance in Gram-negative bacteria[J].mSystems, 2019, 4(6):e00465-19. [53] DING T, LI T, LI J.Identification of natural product compounds as quorum sensing inhibitors in Pseudomonas fluorescens P07 through virtual screening[J].Bioorganic & Medicinal Chemistry, 2018, 26(14):4088-4099. [54] BALTZ R H.Natural product drug discovery in the genomic era:Realities, conjectures, misconceptions, and opportunities[J].Journal of Industrial Microbiology & Biotechnology, 2019, 46(3-4):281-299. [55] MOK S, ASHLEY E A, FERREIRA P E, et al.Drug resistance.Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance[J].Science, 2015, 347(6220):431-435. [56] SINGHANIA A, WILKINSON R J, RODRIGUE M, et al.The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosis[J].Nature Immunology, 2018, 19(11):1159-1168. [57] CANELLAS A L B, DA COSTA W F, FREITAS S J, et al.In sickness and in health:Insights into the application of omics in aquaculture settings under a microbiological perspective[J].Aquaculture, 2022, Online ahead of print. [58] MAHDAVI MASHAKI K, GARG V, NASROLLAHNEZHAD GHOMI A A, et al.RNA-Seq analysis revealed genes associated with drought stress response in kabuli chickpea (Cicer arietinum L.)[J].PLoS One, 2018, 13(6):e0199774. [59] ZHU J H, WANG B W, PAN M, et al.Rifampicin can induce antibiotic tolerance in mycobacteria via paradoxical changes in rpoB transcription[J].Nature Communications, 2018, 9(1):4218. [60] CHOE D, SZUBIN R, DAHESH S, et al.Genome-scale analysis of methicillin-resistant Staphylococcus aureus USA300 reveals a tradeoff between pathogenesis and drug resistance[J].Scientific Reports, 2018, 8(1):2215. [61] ZHAO J, CHEAH S E, ROBERTS K D, et al.Transcriptomic analysis of the activity of a novel polymyxin against Staphylococcus aureus[J].mSphere, 2016, 1(4):e00119-16. [62] QIN H, LO N W, LOO J F, et al.Comparative transcriptomics of multidrug-resistant Acinetobacter baumannii in response to antibiotic treatments[J].Scientific Reports, 2018, 8(1):3515. [63] HAN M L, LIU X, VELKOV T, et al.Metabolic analyses revealed time-dependent synergistic killing by colistin and aztreonam combination against multidrug-resistant Acinetobacter baumannii[J].Frontiers in Microbiology, 2018, 9:2776. [64] HOERR V, DUGGAN G E, ZBYTNUIK L, et al.Characterization and prediction of the mechanism of action of antibiotics through NMR metabolomics[J].BMC Microbiology, 2016, 16:82. [65] ZHAO J, HAN M L, ZHU Y, et al.Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii[J].Biochemical Pharmacology, 2021, 184:114400. [66] SCHELLI K, ZHONG F, ZHU J.Comparative metabolomics revealing Staphylococcus aureus metabolic response to different antibiotics[J].Microbial Biotechnology, 2017, 10(6):1764-1774. [67] CAMPOS A I, ZAMPIERI M.Metabolomics-driven exploration of the chemical drug space to predict combination antimicrobial therapies[J].Molecular Cell, 2019, 74(6):1291-1303.e6. [68] ABREU A C, COQUEIRO A, SULTAN A R, et al.Looking to nature for a new concept in antimicrobial treatments:Isoflavonoids from Cytisus striatus as antibiotic adjuvants against MRSA[J].Scientific Reports, 2017, 7(1):3777. [69] MAIFIAH M H, CREEK D J, NATION R L, et al.Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii[J].Scientific Reports, 2017, 7:45527. [70] LIAW C C, CHEN PC, SHIH C J, et al.Vitroprocines, new antibiotics against Acinetobacter baumannii, discovered from marine Vibrio sp.QWI-06 using mass-spectrometry-based metabolomics approach[J].Scientific Reports, 2015, 5:12856. |